Skip to main content
Top
Published in: Familial Cancer 3/2018

01-07-2018 | Short Communication

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer

Authors: Donika Saporito, Pamela Brock, Heather Hampel, Jennifer Sipos, Soledad Fernandez, Sandya Liyanarachchi, Albert de la Chapelle, Rebecca Nagy

Published in: Familial Cancer | Issue 3/2018

Login to get access

Abstract

Familial non-medullary thyroid cancer (FNMTC) is clinically defined as two or more first-degree relatives with NMTC and appears to follow an autosomal dominant inheritance pattern. Approximately 5–7% of NMTC is hereditary and affects multiple generations with a young age of onset. The primary aim of this study was to determine the age-specific penetrance of NMTC in individuals from a large family with FNMTC with a previously identified private mutation at 4q32, with a secondary aim to determine the penetrance for benign thyroid disease in this family. We present a large family with NMTC in which we had previously described a culpable mutation. Participants provided their personal medical history and family history. The germline 4q32 A > C mutation was detected in 34 of 68 tested individuals. Age-specific penetrance of thyroid cancer and benign thyroid disease was determined using the inverted Kaplan–Meier method of segregation analysis. Individuals who tested positive for the 4q32 mutation have a 68.9% (95% CI 46.5–88.7) risk of developing thyroid cancer by age 70 and a 65.3% (95% CI 46.0–83.8) risk of developing benign thyroid disease by age 70. The 4q32 A > C mutation significantly increases the risk to develop thyroid cancer but not benign thyroid disease in members of this family. The female:male sex ratio of 1.33 that we observed in affected mutation carriers differs greatly from the ratio of approximately 3:1 observed in PTC, supporting a central role of the mutation. Early thyroid surveillance with annual ultrasound is recommended to individuals testing positive for this private familial mutation.
Appendix
Available only for authorised users
Literature
2.
go back to reference DeLellis RA (2004) Pathology of genetics and tumours of endocrine organs. IARC Press, Lyon DeLellis RA (2004) Pathology of genetics and tumours of endocrine organs. IARC Press, Lyon
3.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefPubMedPubMedCentral
4.
go back to reference Sippel RS, Caron NR, Clark OH (2007) An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg 31(5):924–933CrossRefPubMed Sippel RS, Caron NR, Clark OH (2007) An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg 31(5):924–933CrossRefPubMed
5.
go back to reference Bauer JB (2013) Endocrine tumor syndromes and their genetics: clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. Karger, Bethesda Bauer JB (2013) Endocrine tumor syndromes and their genetics: clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. Karger, Bethesda
6.
go back to reference Czene K, Lichtenstein P, Hemminki K (2002) Environmental and heritable causes of cancer among 9.6 million individuals in the swedish family-cancer database. Int J Cancer 99(2):260–266CrossRefPubMed Czene K, Lichtenstein P, Hemminki K (2002) Environmental and heritable causes of cancer among 9.6 million individuals in the swedish family-cancer database. Int J Cancer 99(2):260–266CrossRefPubMed
7.
go back to reference Goldgar DE, Easton DF, Cannon-Albright LA et al (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86(21):1600–1608CrossRefPubMed Goldgar DE, Easton DF, Cannon-Albright LA et al (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86(21):1600–1608CrossRefPubMed
8.
go back to reference He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K et al (2013) Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance. PLoS ONE 8(5):e61920CrossRefPubMedPubMedCentral He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K et al (2013) Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance. PLoS ONE 8(5):e61920CrossRefPubMedPubMedCentral
9.
go back to reference Bradly DP et al (2009) Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery 146(6):1099–1104CrossRefPubMed Bradly DP et al (2009) Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery 146(6):1099–1104CrossRefPubMed
Metadata
Title
Penetrance of a rare familial mutation predisposing to papillary thyroid cancer
Authors
Donika Saporito
Pamela Brock
Heather Hampel
Jennifer Sipos
Soledad Fernandez
Sandya Liyanarachchi
Albert de la Chapelle
Rebecca Nagy
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0048-0

Other articles of this Issue 3/2018

Familial Cancer 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine